BioPharmX Presents BPX-01 Topical Minocycline Gel Acne Data at SDEF's 17th Annual Las Vegas Dermatology Seminar

MENLO PARK, Calif., Nov. 10, 2016

Presentation Details:

Title: "BPX-01 Minocycline 1% topical Gel for the Treatment of Acne Vulgaris"
Author: AnnaMarie Daniels
Location: The Cosmopolitan Las Vegas, 4^th Floor, Belmont 4-8 Ballroom
Dates: November 10-12, 2016

The poster will show that daily application of BPX-01 one percent topical minocycline gel for four weeks was well tolerated and resulted in a statistically significant reduction in P. acnes bacteria in the per protocol population with no detectable minocycline in the plasma.  Prior observations indicate that BPX-01 was effectively delivered into the pilosebaceous units, which was confirmed clinically by a reduction in P. acnes counts without evidence of systemic exposure. Conversely, our second study indicated that daily administration of oral minocycline for the same period of time resulted in high circulating levels of minocycline.  These two studies suggest that BPX-01 topical minocycline may have a favorable pharmacokinetic advantage over oral minocycline for the treatment of acne vulgaris. A confirmatory phase 2b clinical study to support this observation is in progress.

About BioPharmX® Corporation
BioPharmX Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical company that seeks to provide products through proprietary platform technologies for prescription, over-the-counter and supplement applications in dermatology. To learn more about BioPharmX, visit www.BioPharmX.com.

Forward-Looking Statement
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. This press release contains forward-looking statements about the company's expectations, plans, intentions and strategies, including, but not limited to, statements regarding, the effect of BPX-01 on reducing P. acnes bacteria, the effects of daily administration of oral minocycline and the progression of the confirmatory clinical study. These forward-looking statements may be identified by words such as "plan," "expect," "anticipate," "believe," or similar expressions that are intended to identify such forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements, including but not limited to the sufficiency of our resources and our ability to raise additional capital to continue our development programs, our ability to successful develop and commercialize potential product candidates, as well as other risk and uncertainties associated with the process of discovering, developing and commercializing drug candidates that are safe and effective for use as human therapeutics. The risks and uncertainties also include those described in the company's filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended January 31, 2016 and our Quarterly Reports on Form 10-Q. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

BioPharmX is a registered trademark of BioPharmX, Inc.